PROTON-TECHNOLOGIES
The Kopahawakenum (Cree for “Kicking up the dust”) 15-Megawatt Flare Gas to Power Facility announced by SaskPower, Flying Dust First Nation, and Genalta Power, online 2023, plans to purchase Flare Gas from Proton Canada’s nearby asset, according to a letter of intent recently signed between the CEO of Genalta, Paul Miller, and the CEO of Proton, Grant Strem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220404005320/en/
To ensure sufficient supply for the Kopahawakenum Facility, plus Proton’s own 4.2 MW Power Purchase Agreement and other off-takers, the plan is to install a Cryogenic Air Separation unit (ASU), for injecting pure oxygen and third-party CO2 into Proton’s underground oil deposit to increase hydrogen-productive reactions.
Cold gases from the ASU can separate produced gases by freezing or liquifying these at various cold temperatures at the surface using passive heat exchange. Unwanted components like CO2 are planned to go back into the ground, where reactions can cause them to solidify into forms like carbonate rock. Proton has been demonstrating their patented method for accelerating carbonate creation within pores in the earth, by injecting steam boiler blow-down (reactive waste stream fluid) into their CO2-rich subsurface environment.
Proton’s PPA has final approval and plans and designs for construction are underway. Genalta’s Kopahawakenum PPA is conditionally approved under Saskatchewan’s Oil and Gas Processing Investment Incentive (OGPII), and the Saskatchewan Petroleum Innovation Incentive (SPII), which provide royalty credits at a rate of 15% and 25% of expenses respectively, after the private investments are made.
Grant Strem said, “I want to thank Genalta, the government of Saskatchewan, the First Nations Power Authority, and the Flying Dust First Nation for boldly and creatively enabling improvements over our current energy systems. There will be economic and ecological benefits from this first project, and we believe also from hundreds or even thousands of larger similar projects around the world in the long course of time, thanks to the efforts and investments of those involved in this global first. Proton is very pleased to have Genalta as our creative, positive customer. This flex-fuel offtake deal helps justify and enable a “small enough to be fast” commercial demonstration of core elements of Proton’s method to produce low cost hydrogen while sequestering carbon inside the earth as rock. Many oil assets late in their productive life cycle can be repurposed to make clean energy, leveraging the infrastructure and investments of the past. We plan to expand as fast as we can afford to.”
Paul Miller said, “Kopahawakenum is a cornerstone project that will help the energy industry in Saskatchewan to meet the goals announced by the federal government to reduce GHG emissions 30% in the industry by 2030. Additionally it will be including First Nations in energy stewardship in the province in a meaningful way, creating long term jobs and a replicable approach to utilizing Flare and Vent Gas for power generation. Proton’s fuel supply is critical for the Kopahawakenum project. We thank Proton for their collaboration and support; their visionary project is a game changer in the energy industry with tremendous potential to provide large quantities of emissions free fuel at an economical price to the global market. We are proud to be working with them to further reduce emissions in Saskatchewan and hope to utilize their clean Hydrogen in the future as we continue to expand our clean power base in the province.”
For more information please contact info@proton.energy or investorrelations@proton.energy .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005320/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
